Keystone Symposia

Fairmont Chateau Whistler Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2020


Here are the related meetings in 2020:
Emerging Cellular Therapies: Cancer and Beyond (Q1)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

MEETING CANCELLED: Advances in Cancer Immunotherapy (C4)


Organizer(s) Antoni Ribas, W. Nicholas Haining and Priti Hegde
March 22—26, 2020
Fairmont Chateau Whistler • Whistler, BC Canada
Discounted Abstract Deadline: Nov 19, 2019
Abstract Deadline: Dec 17, 2019
Scholarship Deadline: Nov 19, 2019
Discounted Registration Deadline: Jan 22, 2020

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Sponsored by Bayer AG, BioLegend, Inc., Compass Therapeutics, Gilead Sciences, Inc., Genentech, Inc., Incyte Corporation, MorphoSys AG, Nektar Therapeutics, Surface Oncology and TCR² Therapeutics

Summary of Meeting:
Cancer immunotherapy by blocking immune inhibitory checkpoints or engineering T cells for adoptive cell transfer is providing an unprecedented level of long-term antitumor activity in patients with several metastatic cancers. However, the majority of patients with advanced cancers still do not experience sustained clinical benefit from immunotherapy. Understanding the mechanistic basis of response and resistance to these therapies and how therapeutic approaches could best be combined will be essential to continue progress. The largest human experiment is currently being conducted with over 1,000 agents and combinations. Understanding the results to date and determining what is working and what combinations are not working will be important to refine our understanding of immunity in patients with cancer. Questions that remain unanswered include: What is the rationale for the multiple immuno-oncology (IO) combinations being tested in the clinic, how do cancers adapt and resist T cell attack, and can we better understand the tumor microenvironment, thus paving the way for new approaches to cancer therapy. New analyses of patient-derived samples provide information on adaptive and genetic resistance mechanisms to immunotherapy. The conference program will include sessions which cover topics such as new analysis techniques, methodologies, and how to integrate high throughput data to provide a more comprehensive understanding of cancer and the immune system. Participants will leave the conference with an understanding of how the advancement of cancer biology will be influenced by a better comprehension of tumor immunology.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


Program is being updated. Please check back soon for program details.